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We also evaluated small and large shift scenarios of 7.8% and 20.2%, respectively. 
We calculated the incremental QALYs, costs, and cost-effectiveness ratio (ICER) in 
each scenario. RESULTS: The assay strategy was dominant in all scenarios evalu-
ated. In the 5-year and lifetime horizon analyses, the assay resulted in 0.02 and 0.04 
more QALYs and $780 and $730 less in costs, respectively. The small and large shift 
scenarios resulted 0.02 and 0.05 more QALYs, and $5 and $1,300 less in costs over 
a lifetime horizon, respectively. The ICER was most sensitive to the assay cost, the 
AS health state utility, and the proportion of low-risk patients receiving AS in usual 
care. CONCLUSIONS: Our results suggest that the 8-protein prognostic assay is 
potentially cost-effective vs. usual care in patients with Gleason 3+3 & 3+4 prostate 
cancer. Future studies will evaluate the impact of the assay on patient/physician 
treatment choices in real-world settings.
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OBJECTIVES: To perform a cost-effectiveness analysis of Panitumumab+FOLFOX vs 
Bevacizumab+FOLFOX as first-line treatment on RAS-WT mCRC patients from the 
Mexican public healthcare system perspective. METHODS: The evaluation was per-
formed using a Markov model that simulates a hypothetical cohort of patients over 
seven health-stages in two-week transition cycles. Progression-free survival (PFS) 
and overall survival (OS) were used as reported in the PEAK trial. Resource use was 
obtained from five oncologists at four public healthcare institutions. Costs include 
chemotherapy, follow-up, adverse events, metastasis resection, second-line treat-
ment, palliative care, and funeral costs. Mexican Social Security Institute costs were 
applied. Costs and benefits are discounted at 5% for a 10-year time line. Additionally, 
a cost-minimization vs Cetuximab was performed due to equivalence in OS described 
in the ASPECCT trial and similar values of PFS and OS reported in first line for compa-
rable populations. RESULTS: The total costs are $1,048,009.42 for Panitumumab (mean 
life of 3.47 years), and $872,201.70 for Bevacizumab (mean life of 2.80 years), with a 
mean cost-effectiveness ratio per month of OS of $25.173 and $25.932, respectively. 
The 10-month projection for anti-EGFR therapies reveals a total cost of $779,873.60 
for Panitumumab and $1,119,871.90 for Cetuximab, which represents savings of 
$339,998.30 (30.4%) per patient. CONCLUSIONS: Panitumumab as first-line treat-
ment improves the clinical parameters of RAS-WT mCRC patients and presents a 
mean cost-effectiveness ratio similar to Bevacizumab in this population. Regarding 
to Cetuximab, Panitumumab is a cost-saving strategy, with reduction in total costs of 
treatment and administration for public healthcare institutions in Mexico.
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OBJECTIVES: Colorectal cancer is the second cause of cancer-related mortal-
ity worldwide. In Brazil, the National Cancer Institute estimated the occurrence 
of 32,600 new colorectal cancer cases (15,070 cases in males and 17,530 cases in 
females) for 2014. Considering the disease impact and the recent findings of relevant 
clinical trials under new biomarkers’ evaluations in the RAS gene, we developed a 
cost-effectiveness analysis evaluating the use of cetuximab in combination with 
FOLFIRI (folinic acid, fluorouracil and irinotecan) compared to FOLFIRI alone for met-
astatic colorectal cancer (mCRC) in RAS wild-type patients, in the public health care 
system in Brazil. METHODS: To estimate the costs and outcomes of the treatments 
we designed a Markov model in which patients with mCRC were evaluated consider-
ing the natural course of the disease during a time horizon of 10 years. The outcomes 
were evaluated in terms of life year saved. Efficacy data was retrieved primarily from 
the CRYSTAL trial, recently evaluated in light of the new RAS biomarker. Only direct 
2014 medical costs were considered. Costs were obtained from the public database 
DATASUS. Costs and outcomes were discounted to present value at a 5% annual 
rate. RESULTS: In the comparison with cetuximab+FOLFIRI vs FOLFIRI, the incre-
mental effectiveness estimated was 0.7 life years, with an incremental cost of BRL 
46,007.34, representing a cost-effectiveness ratio of 66,090.91. Considering a GDP per 
capita of BRL 24,065.00, the ICER calculated could be considered cost-effective since 
it would fall under the threshold of 3 times the GDP per capita. CONCLUSIONS: 
Cetuximab+FOLFIRI has shown to be cost-effective in mCRC RAS wild-type patients, 
enabling a significant and clinically meaningful increase in survival supported by 
the new findings from the CRYSTAL trial in the RAS population subgroup.
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OBJECTIVES: To evaluate the cost-effectiveness of conventional Transarterial 
chemoembolization with Lipiodol (cTACE) compared to Drug-Eluting-Bead-
Chemoembolization (DEB TACE) in patients with hepatocellular carcinoma (HCC) from 
the Ministry of health perspective. METHODS: A decision tree model was developed 
based on the Egyptian clinical practice, and was derived from published sources. This 
decision analytical model was constructed to assess the costs and consequences 
associated with cTACE compared with DEB TACE. The clinical parameters were derived 
from a comparative study previously published. Direct medical costs were obtained 
from the Ministry of health hospitals in Egypt. Deterministic sensitivity analyses 
were conducted. No discounting was conducted. RESULTS: The total survival days of 
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OBJECTIVES: To analyze the cost-effectiveness of imatinib as first-line therapy from 
2016-2021 compared to physician’s choice of other approved second-generation 
tyrosine kinase inhibitors (TKIs) dasatinib or nilotinib in chronic myeloid leukemia 
in chronic-phase (CML-CP), once imatinb loses patent exclusivity. METHODS: A 
Markov model simulating “imatinib-first” compared to “physician choice” in treat-
ing CML-CP in 2016 through 5 years from the U.S. commercial payer perspective. 
In both approaches, if initial treatment fails, patients are switched to second-gen-
eration TKIs. Patients switch if they fail efficacy endpoints: 12-month complete 
cytogenetic response (CCyR); or 3-month early molecular response (EMR). Patients 
are then followed from switching through overall survival. They can also dete-
riorate to accelerated phase/blast crisis or death. The model assumes stabilized 
prices of second-generation TKIs, but adjusts the price of imatinib to be 100% of 
the branded price for first 6-months, 60-80% for the second 6-months and 10-30% 
thereafter based on patent expiration. For each drug, probabilities of treatment 
choice, switching and failure were meta-analyzed from published clinical trials. 
Quality-adjusted life years (QALYs) were based on US-societal health utilities. Direct 
medical costs per patient were calcated from Marketscan commercial claims (2011-
2012), including annual drug prices. 2013 U.S.-dollars and QALYs were discounted 
at 3%. Univariate and multivariate sensitivity analyses tested parameters with 
greatest impact on results. Findings were interpreted from a willingness-to-pay of 
$100,000/QALY. RESULTS: Based on a 12-month CCyR, imatinib-first ($270,772; 3.80 
QALYs) was cost-effective compared to physician choice ($361,935; 3.93 QALYs), an 
incremental cost-effectiveness ratio (ICER) of $701,000/QALY. The ICER based on 
3-month EMR was $470,000/QALY. Results were robust to uncertainty. The proba-
bilistic sensitivity analysis demonstrated that imatinib-first was cost-effective in 
99% of simulations. CONCLUSIONS: When imatinib loses patent protection in 2016 
in the U.S. and its price declines, it will be the cost-effective treatment strategy for 
CML-CP compared to dasatinib and nilotinib.
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OBJECTIVES: Patients with HER2-positive metastatic breast cancer (MBC) who 
receive Trastuzumab and/or taxanes often need treatment with different agents, 
such as Ado-trastuzumab emtansine (TDM-1) or a combination of Lapatinib and 
Capecitabine (L+C), when disease progresses. Although TDM-1 has better efficacy in 
improving survival, its high cost compared to L+C needs further economic evalua-
tion. This study aimed to assess the cost-effectiveness of TDM-1 compared to L+C in 
MBC patients from a U.S. payer’s perspective. METHODS: A Markov model depicting 
MBC progression for a total of 120 21-day treatment cycles (6.9 years) was devel-
oped. Clinical endpoints in the model included progression-free survival and overall 
survival. The model included the impact of disease progression and toxicity from 
cancer drugs. Cancer drug toxicities included were thrombocytopenia, neutropenia, 
hepatotoxicity, peripheral neuropathy, and pulmonary toxicity. Effectiveness inputs 
were derived from a Phase-III clinical trial comparing TDM-1 and L+C; cost and 
utility inputs from published literature and expert opinion. All cost inputs were 
expressed in 2014 U.S. dollars. The incremental cost-effectiveness ratio (ICER) was 
calculated using quality-adjusted life years (QALY) as the effectiveness measure. 
One-way sensitivity analyses were performed. RESULTS: Patients receiving TDM-1 
cost $241,109 with 1.88 QALYs gained over the 6.9 years, compared with $200,541 
and 1.56 QALYs in L+C group. The base-case ICER was $124,247/QALY. Compared 
to L+C, patients treated with TDM-1 had an expected 0.45 years longer survival 
and 0.31 years longer progression-free survival. The ICER varied from $70,270 to 
$178,223 per QALY when the TDM-1 cost changed from 80 to 120% of its current 
price. CONCLUSIONS: The determination of TDM-1 being cost-effective for MBC 
patients depends on the willingness-to-pay threshold used. Patients derived sig-
nificant life expectancy gains from TDM-1, leading to longer treatment with this 
costly agent.
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OBJECTIVES: Clinico-pathologic factors alone are insufficient to predict the likeli-
hood of progression of Gleason 3+3 & 3+4 prostate cancer. Therefore, many patients 
receive treatment, despite having unaggressive tumors. A novel prognostic assay 
(ProMark™) that uses quantitative measurements of protein biomarkers has been 
validated to predict prostate cancer aggressiveness at the time of biopsy. Our objec-
tive was to evaluate the potential cost-effectiveness of using this 8-protein assay to 
inform treatment decisions. METHODS: We developed a Markov model to estimate 
quality-adjusted life-year (QALY) and cost outcomes for assay and usual care (NCCN 
guidelines) strategies over 5-year and lifetime horizons. The proportion of patients 
classified as low, intermediate, and high-risk for each strategy was derived from 
the assay’s validation study. Treatment distributions, costs, utilities, and mortality 
were derived from the peer-reviewed literature. In the base case, we assumed an 
increase in the use of active surveillance (AS) vs treatment of 14.5% (vs usual care). 
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for the intervention and comparator arms were sourced from relevant clinical tri-
als; survival was assumed to follow an exponential distribution. Representative 
acquisition, administration, and monitoring costs were sourced from the litera-
ture and health technology assessment appraisals. The maximum CEP for each 
analogue was evaluated at two different willingness-to-pay (WTP) thresholds: 
£20,000/QALY and £50,000/QALY. All costs and outcomes were discounted at 
3.5%. RESULTS: The results from the early economic model suggested that neither 
pertuzumab nor trametinib would ever be a cost-effective therapy even at a WTP 
threshold of £50,000. However, at both WTP thresholds of £20,000 and £50,000/
QALY, idelalisib was projected to have a cost-effective price, which was similar 
to the current list price in the UK. CONCLUSIONS: These results demonstrate 
that neither pertuzumab nor trametinib have CEPs, while the CEP for idelalisib is 
similar to the UK launch price, demonstrating that add-on branded therapies co-
administered without anchors dosed to progression (here, rituximab) will permit 
higher prices while remaining cost-effective. This analysis highlights the utility 
of early economic models in evaluating potential pricing and HTA barriers early 
in the development process.
PCN98
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OBJECTIVES: The purpose of this study was to evaluate the maximum cost-effective 
price (CEP) supported for innovative drugs co-administered with existing branded 
therapies. METHODS: An early economic model was constructed in Microsoft 
Excel using a three-state partitioned-survival approach. The intervention arm was 
assumed to be a hypothetical regimen consisting of an add-on drug and an anchor 
branded therapy, while the comparator consisted of the anchor therapy; both arms 
were dosed to progression. Three pricing scenarios were evaluated for the anchor: 
£1,000/month (low cost), £3,000/month (moderate cost), and £5,000/month (high 
cost). Other costs were sourced from a literature review; adverse event costs were 
not included. Progression-free survival (PFS) and overall survival (OS) were modelled 
assuming an exponential distribution; different median PFS and OS gains were 
evaluated to determine the maximum cost-effective price permitted for the add-on 
therapy. The maximum supported price was evaluated at two different willingness-
to-pay (WTP) thresholds: £20,000/QALY and £50,000/QALY. All costs and outcomes 
were discounted at 3.5%. RESULTS: For small gains in OS and PFS (< 3 months), the 
model projects that no CEP for the add-on would be supported at a WTP threshold 
of £20,000/QALY. When administered with a low-cost anchor, the add-on would 
be cost-effective at a WTP of £50,000/QALY with a price up to £583/month; when 
administered with a high-cost therapy, no CEP was supported. In order to sup-
port any CEP for the add-on, substantial gains in OS are required: for a PFS gain 
of 3 months, a gain of 6.9 months for OS would be required at a WTP of £50,000/
QALY. CONCLUSIONS: These results demonstrate that new drugs co-administered 
with anchor branded therapies require substantial OS gains to support cost-effective 
pricing, as these drugs are dosed to progression. This analysis highlights the utility 
of early economic models in evaluating potential pricing and HTA barriers early in 
the development process.
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OBJECTIVES: To evaluate a new empirical algorithm for selecting disease-
related medical billing codes associated with chronic lymphocytic leukemia 
(CLL). METHODS: Patients in the SEER-Medicare database with a CLL diagnosis 
(2002 to 2010) were age/gender matched to a non-cancer sample. A proprietary cod-
ing algorithm based on code frequency (sensitivity, specificity precision or accuracy) 
and cost was used to identify procedure (i.e., CPT and HCPCS) and diagnosis (ICD-
9-CM) codes that differed between the CLL and non-cancer groups. Summarized 
costs for claims with the empirically identified codes were compared to a traditional 
approach of identifying disease-related claims based on presence of a CLL diagnosis 
in the first diagnosis field. The code set was applied to a sample from a prior CLL 
study conducted with commercial claims to assess generalizability. RESULTS: The 
analysis evaluated 10,531 unique billing codes with total costs of > $1 billion (US; CLL 
58.3%; non-cancer 41.7%) for 7,050 age and gender matched SEER-Medicare subjects 
per group. The empirical algorithm found 333 codes that identified 25.0% of the CLL 
group costs as cancer-related. The traditional approach used claims that contained 
2,001 codes and identified a much lower 14.6%. Approximately 1% of costs were 
potentially misidentified in the non-cancer cohort, providing further confirmation 
of the codes selected by the empirical method. Qualitative review of codes revealed 
stronger content validity with the empirical approach compared to the traditional 
approach. Application of codes identified in the SEER-Medicare data to the com-
mercial database provided validation by identifying almost twice as many costs 
as the traditional approach with a 1% error rate. CONCLUSIONS: The traditional 
approach underreports costs and captures costs from procedure codes that do not 
appear to be cancer-related. Use of an empirical approach to identify disease-related 
diagnosis and procedure codes will increase content validity.
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OBJECTIVES: To examine hospital utilization in patients diagnosed with mantle 
cell lymphoma (MCL). METHODS: A retrospective cross-sectional study was con-
cTACE strategy was estimated to be 414 days whereas that of DEB TACE strategy was 
estimated to be 651 days. The total costs for cTACE strategy and DEB TACE strategy 
were EGP 420,529 and EGP 1,351,105 respectively. Thus the incremental cost effec-
tiveness ratio (ICER) for cTACE versus DEB TACE is EGP 3,926 per one day survival 
gained. The Deterministic sensitivity analysis demonstrated that survival associated 
by DEB TACE strategy and DEB-TACE operation costs have the greatest effect on the 
results. CONCLUSIONS: Results from this study suggest that employing a cTACE 
strategy is cost-effective intervention compared to DEB TACE in patients with hepa-
tocellular carcinoma based on the willingness to pay threshold stated by world health 
organization (3xGDP/capita) for low and middle income countries.
PCN95
Cost-effiCACy ANAlysis of iPilumumAb iN Peru
Garrido Lecca S.1, Donato B.M.2, Juarez-Garcia A.3
1Bristol-Myers Squibb, Lima, Peru, 2Bristol-Myers Squibb Company, Wallingford, CT, USA, 
3Bristol-Myers Squibb Company, Mexico City, Mexico
OBJECTIVES: Pricing and reimbursement is typically approached product by prod-
uct, not in comparison across therapeutic areas in Peru. Within oncology, there are 
relatively few treatment options for advance stage cancer patients that have docu-
mented significant increases in overall survival (OS). Ipilumumab has been recently 
approved in Peru for the treatment of unresectable or metastatic melanoma. Given 
the rising costs of cancer care payers and physicians need to better understand 
the value of innovative oncology drugs for reimbursement decision making. This 
study assesses the cost per additional month of mean overall survival of ipilimumab 
and how this metric compares to other oncology agents approved in Peru in the 
metastatic setting. METHODS: We selected agents that received regulatory authori-
zation in the last 10 years in Peru and had phase 3 studies with OS as a primary or 
secondary objective. Mean OS was obtained from published literature. Drug prices 
were obtained from “observatorio de precios de DIGEMID” a public database. The 
economic value of each asset is presented in terms of cost per additional month of 
mean OS from a private healthcare payer perspective. The analysis uses the cost 
to treat to mean progression of each agent divided by the months of mean overall 
survival improvement using its current list price. All prices are in 2014 “nuevos 
soles” RESULTS: Seventeen drugs met inclusion criteria. Of these, 26 different indi-
cations were evaluated. The average cost per mean overall survival month gained 
was estimated at S/.57,178, range S/.3,108 – S/.264,764. Ipilimumab as first and sec-
ond line treatment for metastatic melanoma had an estimated cost per additional 
mean overall survival at S/.36,901 and S/.41,740 respectively. CONCLUSIONS: In 
this cost efficacy analysis, Ipilimumab´s cost per additional month of overall sur-
vival was estimated below the market average. At current private market prices 
Ipilimumab may offer good value for money.
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OBJECTIVES: Recent findings show that vaccinating older men who have sex with 
men (MSM) with history of high-grade anal intraepithelial neoplasia (HGAIN)–a 
precursor to anal cancer–with quadrivalent human papillomavirus (qHPV) vac-
cine was associated with 50% decrease in the hazards for recurrent or persistent 
HGAIN. We evaluated the long-term clinical and economic outcomes of adding 
qHPV vaccine to the HGAIN treatment regimen HGAIN in HIV-positive MSM aged ≥ 
27 years. METHODS: Using Markov model of anal histology in HIV-positive MSM we 
compared two strategies–no qHPV vaccination after treatment for HGAIN versus 
qHPV vaccination after treatment for HGAIN. The probability of anal intraepithelial 
neoplasia (AIN) progression was conditional on patients’ CD4 count. Model param-
eters, including baseline prevalence, disease transitions, costs, and utilities were 
either obtained from literature or calibrated using a natural history model of anal 
carcinogenesis. Model output included lifetime costs, quality-adjusted life years 
(QALYs), and lifetime risk of developing invasive cancer. Results from the healthcare 
perspective were presented in the forms of incremental cost-effectiveness ratios 
(ICERs) and decrease in lifetime risk of anal cancer. Deterministic and probabilistic 
sensitivity analyses were conducted on model parameters. RESULTS: Vaccination 
after treatment for HGAIN decreased the lifetime risk of anal cancer by 63% com-
pared to the no vaccination strategy. Vaccination resulted in the decrease in lifetime 
costs with increase in effectiveness by 0.16 QALYs. The predicted incidence of anal 
cancer after vaccination was almost one-third to that of the no vaccination strategy. 
The results were sensitive to the model parameters–progression from HGAIN to 
cancer, mortality attributed to anal cancer, cost of HGAIN treatment, and discount 
rate. CONCLUSIONS: Vaccinating the high-risk population of HIV-positive MSM aged 
≥ 27 after treatment for HGAIN is a cost-saving strategy. Expansion of current vac-
cination guidelines to include this population should be a priority.
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oNCology ProduCts: PrediCtioNs from AN eArly eCoNomiC model
Smith NJ1, Cordina G1, Cheynel J2, Blissett D2, Beckerman R1
1CBPartners, New York, NY, USA, 2CBPartners, London, UK
OBJECTIVES: The purpose of this study was to develop an early economic model to 
compare the maximum supported cost-effective prices (CEP) of recently launched 
co-administered branded products to their list prices in the UK. METHODS: An 
early economic model was constructed in Microsoft Excel using a three-state 
partitioned-survival approach. A pragmatic literature search was performed iden-
tified three co-administered branded therapies as case studies: pertuzumab + 
trastuzumab(+docetaxel) in HER2+ breast cancer, trametinib + dabrafenib in mela-
noma, and idelalisib + rituximab in chronic lymphocytic leukaemia; all therapies 
except rituximab were dosed to progression. Progression-free and overall survival 
